Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $24.0 million.

  • Abeona Therapeutics' Operating Expenses rose 5652.0% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.6 million, marking a year-over-year increase of 3763.25%. This contributed to the annual value of $64.2 million for FY2024, which is 2681.15% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Operating Expenses of $24.0 million as of Q3 2025, which was up 5652.0% from $23.2 million recorded in Q2 2025.
  • Abeona Therapeutics' Operating Expenses' 5-year high stood at $49.7 million during Q4 2021, with a 5-year trough of $9.0 million in Q2 2022.
  • For the 5-year period, Abeona Therapeutics' Operating Expenses averaged around $17.2 million, with its median value being $14.6 million (2021).
  • In the last 5 years, Abeona Therapeutics' Operating Expenses soared by 18405.03% in 2021 and then plummeted by 7380.97% in 2022.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Operating Expenses stood at $49.7 million in 2021, then tumbled by 73.81% to $13.0 million in 2022, then rose by 1.58% to $13.2 million in 2023, then rose by 26.22% to $16.7 million in 2024, then surged by 44.06% to $24.0 million in 2025.
  • Its Operating Expenses stands at $24.0 million for Q3 2025, versus $23.2 million for Q2 2025 and $19.7 million for Q1 2025.